Positive survival results for durvalumab, tremelimumab and chemotherapy in metastatic non-small cell lung cancer (NSCLC)

Final analysis of results from the Phase III POSEIDON study show that the combination of durvalumab, tremelimumab and chemotherapy improved overall survival versus chemotherapy alone, with an acceptable safety profile, in the first-line treatment of metastatic NSCLC.

Source:

PharmaTimes